List view / Grid view
Founder and CSO of Achilles Therapeutics Dr Sergio Quezada reveals how the landmark TRACERx study has gleaned key insights that could make the difference between success and failure in immunotherapy treatment.
Cofounder & Chief Scientific Officer of Pheast Therapeutics, Dr Roy Maute, reveals his company’s promising drug candidate and explains why they have focused on their chosen target.
Using shRNA screening enabled researchers to investigate the roles of individual specific factors in maintaining the network found in AML.
22 December 2023 | By
Download this eBook for FREE. Explore cutting-edge immuno-oncology insights through exclusive interviews and studies by leading experts in the field.
Understanding the involvement of Nod1 in the development of blood stem cells could greatly improve blood disorder treatments.
Cancer treatment may be majorly impacted by new findings about the polymerase theta-mediated end joining time DNA repair pathway.
Glioblastomas can resist immunotherapy as perivascular fibroblasts support the creation of an immunosuppressive tumour environment.
NETs require epidermal growth factor to grow, meaning that inhibiting EGF receptors could treat these types of tumours.
In this eBook, discover how to better understand tissue landscapes with different microscopy techniques including multiplex imaging.
Using saturation genome editing, researchers have created a map of disease-causing mutations for neurodevelopmental disorders and cancer.
Intestinal organoids allowed researchers to understand how Rnf43 and Daam1 influence the balance of stem cell renewal and differentiation.
Increasing microRNA-22 overexpression in a gene therapy approach treated HCC in mice, offering promise for its prevention and treatment.
Our inaugural report is an exploration of the remarkable advancements in cancer research and the field of drug discovery.
An advanced computational model enables scientists to study how cancer cells navigate through blood vessels.
New findings about how RBM10 inhibits lung cancer growth offers potential for an anti-cancer drug and more personalised treatment.
